Limits...
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, Boczek U, Stanek K, Kitz J, Wolff HA, Ghadimi BM, Middel P, Liersch T, Rüschoff J, Conradi LC - Oncotarget (2015)

Bottom Line: The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS).Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM.Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

View Article: PubMed Central - PubMed

Affiliation: Department of General, Visceral and Pediatric Surgery, University Medical Center, Göttingen, Germany.

ABSTRACT

Objective: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.

Patients and methods: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.

Results: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037).

Conclusions: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

No MeSH data available.


Related in: MedlinePlus

HER-3 immunohistochemical staining of tissue samples from liver metastasesThis figure pictures tissue samples from HER-3 immunohistochemical staining from CRC liver metastases with various factors of magnification.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4558136&req=5

Figure 2: HER-3 immunohistochemical staining of tissue samples from liver metastasesThis figure pictures tissue samples from HER-3 immunohistochemical staining from CRC liver metastases with various factors of magnification.

Mentions: HER-2 immunostaining was conducted using a PATHWAY® anti-HER-2/neu (4B5) rabbit monoclonal antibody (Ventana Medical Systems, Mannheim, Germany) on a Ventana BenchMark XT immunostainer (Ventana, Tucson, AZ, US) and visualized by the ultraView Universal DAB Detection Kit (Ventana Medical Systems, Mannheim, Germany). HER-3 expression was determined by using the anti c-erbB-3/HER-3 rabbit monoclonal antibody (clone SP71; Spring Bioscience, Pleasanton, USA). Examples of the immunohistological staining of HER-3 are shown in Figure 2.


HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, Boczek U, Stanek K, Kitz J, Wolff HA, Ghadimi BM, Middel P, Liersch T, Rüschoff J, Conradi LC - Oncotarget (2015)

HER-3 immunohistochemical staining of tissue samples from liver metastasesThis figure pictures tissue samples from HER-3 immunohistochemical staining from CRC liver metastases with various factors of magnification.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4558136&req=5

Figure 2: HER-3 immunohistochemical staining of tissue samples from liver metastasesThis figure pictures tissue samples from HER-3 immunohistochemical staining from CRC liver metastases with various factors of magnification.
Mentions: HER-2 immunostaining was conducted using a PATHWAY® anti-HER-2/neu (4B5) rabbit monoclonal antibody (Ventana Medical Systems, Mannheim, Germany) on a Ventana BenchMark XT immunostainer (Ventana, Tucson, AZ, US) and visualized by the ultraView Universal DAB Detection Kit (Ventana Medical Systems, Mannheim, Germany). HER-3 expression was determined by using the anti c-erbB-3/HER-3 rabbit monoclonal antibody (clone SP71; Spring Bioscience, Pleasanton, USA). Examples of the immunohistological staining of HER-3 are shown in Figure 2.

Bottom Line: The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS).Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM.Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

View Article: PubMed Central - PubMed

Affiliation: Department of General, Visceral and Pediatric Surgery, University Medical Center, Göttingen, Germany.

ABSTRACT

Objective: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.

Patients and methods: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.

Results: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037).

Conclusions: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

No MeSH data available.


Related in: MedlinePlus